Technology Transfer Plan. Penwest to provide to Trevi, in accordance with the delivery instructions provided by Trevi, the following archived documents and materials within [**] of the Effective Date, to the extent such documents are contained in the boxes specifically designated for the retention of such documents and in the current possession of Penwest.
Technology Transfer Plan. The Parties shall perform the Technology Transfer in Waves during the TT Term pursuant to the timelines and in accordance with the responsibilities allocated under the Technology Transfer Plan. Each Party shall perform the activities assigned to such Party under the Technology Transfer Plan at the sites identified in Section 2.2.6 and shall perform all such activities in compliance with Applicable Law. Each Party shall be responsible for all salaries and costs and expenses of their own personnel (including, without limitation, travel and living expenses). Without limiting the foregoing, Codexis shall provide Merck the Codexis Methods at dates no later than those set forth in the timelines in the Technology Transfer Plan. Codexis shall promptly transfer to Merck (a) the Initial Technology Transfer Inventory, (b) the Codexis Materials, (c) the Codexis Documentation, and (d) the Codexis Software and other Platform Technology, at dates no later than those set forth in the timelines in Technology Transfer Plan. All Technology Transfer activities shall be performed [***] by the Parties. Notwithstanding anything to the contrary, subject to any updates to the Technology Transfer Plan pursuant to Section 2.2.2, Codexis shall not be obligated to transfer to Merck any information and/or materials not described in the Technology Transfer Plan.
Technology Transfer Plan. Upon delivery by either Party of Notice to terminate this Agreement in its entirety or with respect to any Packaged Product or otherwise at Purchaser’s initiative, the Parties shall meet, develop and mutually agree upon a plan and reasonable timetable (the “Technology Transfer Plan”) under which Packager hereby covenants and agrees that it will use commercially reasonable efforts to assist Purchaser and/or Purchaser’s designee to establish their own Packaging line for the Products in order to enable Purchaser and/or Purchaser’s designee to Package Purchaser’s entire requirement of Packaged Product upon the termination of this Agreement or as soon as commercially practicable thereafter. Separate Technology Transfer Plans may be established with respect to each Packaged Product. Improvements made to the Packaging Process for an Exclusive Product during the term of this Agreement will be transferred to Purchaser as a part of the Technology Transfer Plan. Improvements for a Special Product during the term of this Agreement at a cost of less than $3,000,000 will be transferred to Purchaser as a part of the Technology Transfer Plan. Improvements to Special Products made to the Packaging process during the term of this Agreement at a cost greater than $3,000,000 will be transferred to Purchaser as a part of the Technology Transfer Plan only to the extent that Purchaser shared equally in all costs associated therewith. Packager agrees that it will use reasonable efforts to support such technology transfers to Purchaser and/or its designee which efforts shall include making Packager’s Packaging personnel, including quality and technical personnel, available to provide reasonable technical assistance with the technology transfers and training regarding Purchaser’s Packaging of the Product and any other matters included in the agreed upon Transfer Plan. Purchaser shall be solely responsible for obtaining any and all Regulatory Approvals from the applicable Governmental Authorities for qualification of each new packager and its Packaging facilities. Packager will not be obligated to assist Purchaser in developing a Packaging Process that is different in any manner from the Packaging Process used by Packager to Package the Product. If upon termination of this Agreement, the technology transfer is not complete due to commercially reasonable timelines for such technology transfer extending beyond the Term, Packager will not be responsible for supply interruptions. Purcha...
Technology Transfer Plan. As soon as reasonably practical after the Effective Date, the parties shall meet to agree on a plan for Technology Transfer (the "Technology Transfer Plan"). The Technology Transfer Plan shall specify the Technology Transfer activities to be performed and the amount of time to be devoted to such activities. The parties shall review and update the Technology Transfer Plan, on a monthly basis, until the earlier to occur of (i) completion of Technology Transfer or (ii) the end of the Technology Transfer period, as set forth in Section 3.2. Biogen shall not be required to devote time or perform activities in connection with Technology Transfer beyond the time and activities shown on the Technology Transfer Plan unless both parties agree on an update to the Technology Transfer Plan.
Technology Transfer Plan. With respect to any Licensed Know-How or Licensed Materials not already transferred pursuant to Clause 3.1 prior to the first meeting of the JSC, the JSC shall (subject to Clause 2.4), to the extent a plan for implementing such transfer has not already been put in place, lay down procedures and make such plan (a “Technology Transfer Plan”) or make such changes to the Technology Transfer Plan, as the JSC deems necessary. If any such Licensed Know-How already exists in electronic form, then it shall be transferred in electronic rather than paper form. Following receipt of any Licensed Know-How or Licensed Materials in accordance with this Article 3, Xxxxxxx shall promptly provide Genmab with written acknowledgement of the receipt of such Licensed Know-How and/or Licensed Materials.
Technology Transfer Plan. During the Collaboration Period and thereafter until the [**], Spark will provide Pfizer with reasonable assistance as necessary or desirable to effect the timely and orderly transfer of Spark Technology (other than Manufacturing process technology) to Pfizer (a) for Pfizer’s use to conduct any of its activities under the Product Development Plan, and after the Collaboration Period, Development, Manufacture and Commercialization of the Compounds and Licensed Products and (b) in accordance with the Technology Transfer Plan. Without limiting Spark’s obligations set forth elsewhere under this Section 4.5, Spark will perform all technology transfer activities as set forth under the technology transfer plan set forth in Exhibit C (the “Technology Transfer Plan”). During the Collaboration Period, all out-of-pocket costs and expenses and the costs of Spark’s personnel associated with the transfer of Spark Technology under the Technology Transfer Plan will be borne by Spark. Following the Collaboration Period, all reasonable out-of-pocket costs and expenses and the costs of Spark’s personnel, in excess of the time set forth in Section 4.15, associated with the transfer of Spark Technology under the Technology Transfer Plan will be borne by Pfizer. The Technology Transfer Plan does not include any transfer of Manufacturing process technology. Subject to Section 4.12, Pfizer may request that Spark provide Pfizer or one or more Pfizer Affiliates or Third Parties designated by Pfizer (and, as to Third Parties, approved by Spark as set forth in Section 4.12) with a transfer of Manufacturing process technology relating to Licensed Product(s). The Parties shall negotiate and agree upon a reasonable Manufacturing technology transfer plan and budget therefor, and all reasonable out-of-pocket costs and expenses and the reasonable costs of Spark’s personnel associated with such Manufacturing technology transfer will be borne by Pfizer.
Technology Transfer Plan. Genentech shall provide the following materials and information to Novogen within three (3) months following the Effective Date: Clinical Sciences: XXXXX Regulatory XXXXX Research XXXXX IP/Legal XXXXX CMC XXXXX 45 kg of API XXXXX API to be shipped within ten (10) days of receipt of upfront payment by Genentech. Confidential material omitted and filed separately with the Commission. Drug Product XXXXX XXXXX Confidential material omitted and filed separately with the Commission. EXHIBIT D Novogen Clinical Study Design Preliminary, and Subject to Consultation with Regulatory Agencies and Key Opinion Leaders CLINICAL TRIAL PROTOCOL CONCEPT Proposed Phase II Study of GDC-0084 in Glioblastoma Multiforme
Technology Transfer Plan. Upon the Effective Date the Parties shall commence the Technology Transfer in sequential order of Waves as described in, and in accordance with, the Technology Transfer Plan. Each Party shall perform the activities assigned to such Party under the Technology Transfer Plan at the sites identified in Section 2.2.6 and 2.2.7 and shall perform all such activities in compliance with Applicable Law. Notwithstanding anything to the contrary, subject to any updates to the Technology Transfer Plan pursuant to Section 2.2.4, Codexis shall not be obligated to transfer to GSK any information and/or materials not described in the Technology Transfer Plan.
Technology Transfer Plan. Genmab will transfer or arrange to have transferred, to GSK (at a time to be agreed between them but in any event so as to allow GSK to make such use of the same as may be necessary for the fulfilment of its obligations hereunder) a copy of all preclinical and clinical analytical assays and all clinical data related to any Clinical Studies of the Product conducted, sponsored or funded by Genmab (including investigator sponsored trials), whether written or electronic, including all relevant clinical safety and efficacy data; all regulatory data and information related to the use and sale of the Product and any other Genmab Know-How, in an orderly fashion and in a manner such that confidentiality in such transferred Genmab Know-How is preserved in all material respects. Genmab may retain [***], but agrees that, subject to the foregoing, the same may be used by GSK at no cost [***] as agreed between the Parties to support Development and Manufacturing in furtherance of this Agreement. With respect to any Listed Genmab Know-How not already transferred pursuant to this Clause 4.10 prior to the first meeting of the JSC, the JSC shall put in place procedures and a plan for implementing the transfer, [***] of Genmab Know-How contemplated under this Clause 4.10 (a “Technology Transfer Plan”). If Genmab Know-How already exists in electronic form, then it shall be transferred in electronic rather than paper form. Following receipt of any Genmab Know-How or other material in accordance with this Clause, GSK shall promptly provide Genmab with written acknowledgement of the receipt of the Genmab Know-How.
Technology Transfer Plan. The Parties have established a mutually agreed-upon Technology Transfer Plan to enable Cxxx’x use of ARScience Bio Technology for the Products, included in ARScience Bio Technology (the “Technology Transfer Plan”), attached hereto as Exhibit B. The Parties will use commercially reasonable efforts to carry out the Technology Transfer Plan on the timeline set forth therein.
